Quick Answer
KALA BIO, Inc. reported Cash and Equivalents of $51.18 million for fiscal year 2024.
KALA BIO, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $51.18M | +0.6% |
| 2023 | $50.90M | -27.8% |
| 2022 | $70.50M | -23.5% |
| 2021 | $92.14M | +19.2% |
| 2020 | $77.26M | -9.6% |
| 2019 | $85.45M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.10M | -57.1% | -34.0% |
| June 30, 2025 | $31.94M | -41.1% | -24.3% |
| March 31, 2025 | $42.22M | -12.9% | -17.5% |
| December 31, 2024 | $51.18M | +0.6% | +4.0% |
| September 30, 2024 | $49.20M | -12.2% | -9.2% |
| June 30, 2024 | $54.20M | +10.0% | +11.8% |
| March 31, 2024 | $48.48M | -23.8% | -4.7% |
| December 31, 2023 | $50.90M | -27.8% | -9.2% |
- KALA BIO, Inc. showed an increase of +0.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2024 period, KALA BIO, Inc.’s cash and equivalents has declined by 40.1% (from $85.45 million to $51.18 million).
- The most recent figure is from KALA BIO, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: